ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
August 12, 2021EyeGate Pharmaceuticals, Inc. today announced the closing of its previously announced registered direct offering priced at-the-marked under Nasdaq rules of 4,668,844 shares of its common stock at a purchase price of $2.3025 per share. -
Valeant Pharmaceuticals and EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product
February 22, 2017Valeant Pharmaceuticals International and EyeGate Pharmaceuticals have entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Valeant exclusive,
Pharma Sources Insight January 2025
